{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:59:00Z","timestamp":1780509540267,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Retroperitoneal fibrosis (RPF) is a rare inflammatory disease, that, if left untreated, can lead to ureteral obstruction and subsequent renal impairment. First-line treatment is prednisolone, with rituximab, often used for refractory cases. This study evaluates treatment response in both [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET and CT, and potential baseline parameters for early prediction of progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      50 patients with RPF underwent at least two [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT scans (baseline, BL, and first follow-up, FU1), 36 patients a second (FU2), 18 patients a third follow-up (FU3). PET parameters SUV\n                      <jats:sub>max<\/jats:sub>\n                      , SUV\n                      <jats:sub>mean<\/jats:sub>\n                      , SUV\n                      <jats:sub>peak<\/jats:sub>\n                      , metabolic active volume (MAV), thickness (CT\n                      <jats:sub>rim<\/jats:sub>\n                      ) and cranio-caudal extension (CT\n                      <jats:sub>cc<\/jats:sub>\n                      ) of the retroperitoneal mass were measured. Therapy groups were divided into prednisolone, rituximab and the combination of both.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All PET parameters showed significant correlations with CT\n                      <jats:sub>rim<\/jats:sub>\n                      at all four timepoints. After therapy all PET parameters and CT\n                      <jats:sub>rim<\/jats:sub>\n                      decreased significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.021). Highly significant metabolic and morphologic response was seen in the prednisolone (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.003) and the combination therapy group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.001). At FU2, eight patients showed progression, with MAV as a good predictor of progression in BL (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041; 217.33 versus 100.86\u00a0ml). At FU2, SUV\n                      <jats:sub>max<\/jats:sub>\n                      , SUV\n                      <jats:sub>peak<\/jats:sub>\n                      and MAV differed significantly between progression and non-progression group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.009), while CT showed no significant differences.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings underscore the superiority of PET against CT in therapy monitoring of RPF, especially in the detection of progression at FU2. Higher BL MAV correlated with progression at FU2, indicating its potential as a predictive marker. Still, especially when PET is not available, CT can be considered for initial therapy monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07479-6","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T08:14:20Z","timestamp":1755159260000},"page":"1258-1269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["[18F]FDG PET\/CT for treatment monitoring and prediction of progression in retroperitoneal fibrosis"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7107-3934","authenticated-orcid":false,"given":"Christian","family":"Bayerl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian M. M.","family":"Rogasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Amthauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"Schatka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"van der Giet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"issue":"9506","key":"7479_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0140-6736(06)68035-5","volume":"367","author":"A Vaglio","year":"2006","unstructured":"Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006;367(9506):241\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(06)68035-5.","journal-title":"Lancet"},{"issue":"4","key":"7479_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/MD.0b013e3181afc420","volume":"88","author":"EFH van Bommel","year":"2009","unstructured":"van Bommel EFH, Jansen I, Hendriksz TR, Aarnoudse A. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Med (Baltim). 2009;88(4):193\u2013201. https:\/\/doi.org\/10.1097\/MD.0b013e3181afc420.","journal-title":"Med (Baltim)"},{"issue":"6","key":"7479_CR3","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/sj.ki.5002427","volume":"72","author":"D Corradi","year":"2007","unstructured":"Corradi D, Maestri R, Palmisano A, et al. Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis. Kidney Int. 2007;72(6):742\u201353. https:\/\/doi.org\/10.1038\/sj.ki.5002427.","journal-title":"Kidney Int"},{"issue":"3","key":"7479_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11739-016-1599-z","volume":"12","author":"GM Rossi","year":"2017","unstructured":"Rossi GM, Rocco R, Accorsi Buttini E, Marvisi C, Vaglio A. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. Intern Emerg Med. 2017;12(3):287\u201399. https:\/\/doi.org\/10.1007\/s11739-016-1599-z.","journal-title":"Intern Emerg Med"},{"issue":"10","key":"7479_CR5","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s00259-012-2144-6","volume":"39","author":"G Moroni","year":"2012","unstructured":"Moroni G, Castellani M, Balzani A, et al. The value of (18)F-FDG PET\/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging. 2012;39(10):1635\u201342. https:\/\/doi.org\/10.1007\/s00259-012-2144-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7479_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11739-016-1426-6","volume":"11","author":"C Fofi","year":"2016","unstructured":"Fofi C, Prosperi D, Pettorini L, et al. Diagnosis and follow-up of idiopathic retroperitoneal fibrosis: role of (18)F-FDG-PET\/CT and biochemical parameters in patients with renal involvement. Intern Emerg Med. 2016;11(6):809\u201316. https:\/\/doi.org\/10.1007\/s11739-016-1426-6.","journal-title":"Intern Emerg Med"},{"issue":"3","key":"7479_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejim.2010.02.008","volume":"21","author":"I Jansen","year":"2010","unstructured":"Jansen I, Hendriksz TR, Han SH, Huiskes AW, van Bommel EF. (18)F-fluorodeoxyglucose position emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Eur J Intern Med. 2010;21(3):216\u201321. https:\/\/doi.org\/10.1016\/j.ejim.2010.02.008.","journal-title":"Eur J Intern Med"},{"issue":"5","key":"7479_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11604-012-0066-7","volume":"30","author":"F Bertagna","year":"2012","unstructured":"Bertagna F, Treglia G, Leccisotti L, et al. [(1)(8)F]FDG-PET\/CT in patients affected by retroperitoneal fibrosis: a bicentric experience. Jpn J Radiol. 2012;30(5):415\u201321. https:\/\/doi.org\/10.1007\/s11604-012-0066-7.","journal-title":"Jpn J Radiol"},{"issue":"6","key":"7479_CR9","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.10.046","volume":"71","author":"A Fernando","year":"2017","unstructured":"Fernando A, Pattison J, Horsfield C, D\u2019Cruz D, Cook G, O\u2019Brien T. [(18)F]-Fluorodeoxyglucose positron emission tomography in the diagnosis, treatment stratification, and monitoring of patients with retroperitoneal fibrosis: A prospective clinical study. Eur Urol. 2017;71(6):926\u201333. https:\/\/doi.org\/10.1016\/j.eururo.2016.10.046.","journal-title":"Eur Urol"},{"issue":"5","key":"7479_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/RLU.0b013e3182478bd3","volume":"37","author":"R Guignard","year":"2012","unstructured":"Guignard R, Simukoniene M, Garibotto V, Ratib O. 18F-FDG PET\/CT and contrast-enhanced CT in a one-stop diagnostic procedure: a better strategy for management of patients suffering from retroperitoneal fibrosis? Clin Nucl Med. 2012;37(5):453\u20139. https:\/\/doi.org\/10.1097\/RLU.0b013e3182478bd3.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"7479_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0022-5347(05)64677-0","volume":"168","author":"AH Kardar","year":"2002","unstructured":"Kardar AH, Kattan S, Lindstedt E, Hanash K. Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration. J Urol. 2002;168(2):550\u20135.","journal-title":"J Urol"},{"issue":"5","key":"7479_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1053\/j.ajkd.2007.02.268","volume":"49","author":"EF van Bommel","year":"2007","unstructured":"van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis. 2007;49(5):615\u201325. https:\/\/doi.org\/10.1053\/j.ajkd.2007.02.268.","journal-title":"Am J Kidney Dis"},{"issue":"9788","key":"7479_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0140-6736(11)60934-3","volume":"378","author":"A Vaglio","year":"2011","unstructured":"Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus Tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet. 2011;378(9788):338\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(11)60934-3.","journal-title":"Lancet."},{"issue":"3","key":"7479_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.amjmed.2003.08.033","volume":"116","author":"R Marcolongo","year":"2004","unstructured":"Marcolongo R, Tavolini IM, Laveder F, et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med. 2004;116(3):194\u20137. https:\/\/doi.org\/10.1016\/j.amjmed.2003.08.033.","journal-title":"Am J Med"},{"issue":"3","key":"7479_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/00365599409181272","volume":"28","author":"M Harreby","year":"1994","unstructured":"Harreby M, Bilde T, Helin P, Meyhoff HH, Vinterberg H, Nielsen VA. Retroperitoneal fibrosis treated with Methylprednisolon pulse and disease-modifying antirheumatic drugs. Scand J Urol Nephrol. 1994;28(3):237\u201342.","journal-title":"Scand J Urol Nephrol"},{"key":"7479_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s41927-020-00140-9","volume":"4","author":"V Boyeva","year":"2020","unstructured":"Boyeva V, Alabsi H, Seidman MA, et al. Use of rituximab in idiopathic retroperitoneal fibrosis. BMC Rheumatol. 2020;4:40. https:\/\/doi.org\/10.1186\/s41927-020-00140-9.","journal-title":"BMC Rheumatol"},{"issue":"9","key":"7479_CR17","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/1756-185X.14798","volume":"26","author":"M Oztas","year":"2023","unstructured":"Oztas M, Altun I, Ayla AY, et al. Rituximab in the management of retroperitoneal fibrosis: A single tertiary rheumatology care center experience. Int J Rheum Dis. 2023;26(9):1714\u201321. https:\/\/doi.org\/10.1111\/1756-185X.14798.","journal-title":"Int J Rheum Dis"},{"issue":"42","key":"7479_CR18","doi-asserted-by":"publisher","first-page":"e12631","DOI":"10.1097\/MD.0000000000012631","volume":"97","author":"R Wallwork","year":"2018","unstructured":"Wallwork R, Wallace Z, Perugino C, Sharma A, Stone JH. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Med (Baltim). 2018;97(42):e12631. https:\/\/doi.org\/10.1097\/MD.0000000000012631.","journal-title":"Med (Baltim)"},{"issue":"3","key":"7479_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/annrheumdis-2019-216258","volume":"79","author":"ML Urban","year":"2020","unstructured":"Urban ML, Maritati F, Palmisano A, et al. Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. Ann Rheum Dis. 2020;79(3):433\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216258.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7479_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","volume":"74","author":"MN Carruthers","year":"2015","unstructured":"Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206605.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"7479_CR21","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1007\/s00259-016-3351-3","volume":"43","author":"V Ruhlmann","year":"2016","unstructured":"Ruhlmann V, Poeppel TD, Brandt AS, et al. (18)F-FDG PET\/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. Eur J Nucl Med Mol Imaging. 2016;43(9):1646\u201352. https:\/\/doi.org\/10.1007\/s00259-016-3351-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7479_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejim.2019.01.019","volume":"62","author":"G Morin","year":"2019","unstructured":"Morin G, Mageau A, Benali K, et al. Persistent FDG\/PET CT uptake in idiopathic retroperitoneal fibrosis helps identifying patients at a higher risk for relapse. Eur J Intern Med. 2019;62:67\u201371. https:\/\/doi.org\/10.1016\/j.ejim.2019.01.019.","journal-title":"Eur J Intern Med"},{"key":"7479_CR23","doi-asserted-by":"publisher","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1(Suppl 1):122S-50S. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","DOI":"10.2967\/jnumed.108.057307"},{"issue":"2","key":"7479_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"JH O","year":"2016","unstructured":"O JH, Lodge MA, Wahl RL. Practical PERCIST: A simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576\u201384. https:\/\/doi.org\/10.1148\/radiol.2016142043.","journal-title":"Radiology"},{"issue":"9","key":"7479_CR25","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2967\/jnumed.113.136986","volume":"55","author":"AK Tahari","year":"2014","unstructured":"Tahari AK, Chien D, Azadi JR, Wahl RL. Optimum lean body formulation for correction of standardized uptake value in PET imaging. J Nucl Med. 2014;55(9):1481\u20134. https:\/\/doi.org\/10.2967\/jnumed.113.136986.","journal-title":"J Nucl Med"},{"issue":"1","key":"7479_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/annonc\/mds247","volume":"24","author":"GC Park","year":"2013","unstructured":"Park GC, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY. Prognostic value of metabolic tumor volume measured by 18F-FDG PET\/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Ann Oncol. 2013;24(1):208\u201314. https:\/\/doi.org\/10.1093\/annonc\/mds247.","journal-title":"Ann Oncol"},{"issue":"1","key":"7479_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00259-011-1934-6","volume":"39","author":"S Liao","year":"2012","unstructured":"Liao S, Penney BC, Wroblewski K, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39(1):27\u201338. https:\/\/doi.org\/10.1007\/s00259-011-1934-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7479_CR28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1148\/radiol.2293021168","volume":"229","author":"M Tatsumi","year":"2003","unstructured":"Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeoxyglucose uptake in the aortic wall at PET\/CT: possible finding for active atherosclerosis. Radiology. 2003;229(3):831\u20137. https:\/\/doi.org\/10.1148\/radiol.2293021168.","journal-title":"Radiology"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07479-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07479-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07479-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:46:31Z","timestamp":1769222791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07479-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7479"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07479-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the ethics committee of Charit\u00e9 - Universit\u00e4tsmedizin Berlin (March 3rd, 2025\/EA4\/035\/25).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was not required, as the study exclusively utilized fully anonymized imaging data without any patient-identifying information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}